RATIONALE-303: Long-Term Outcomes of Tislelizumab in Previously Treated Advanced/Metastatic NSCLC
{{output}}
Introduction: RATIONALE-303 (NCT03358875) investigated the efficacy and safety of tislelizumab versus docetaxel in pretreated patients with advanced NSCLC. We present long-term outcomes with an additional 30-month follow-up after... ...
